Beyond consent: Reframing ethical governance in genetic data reuse within clinical trials

Genetic research holds immense potential for advancing personalized medicine, improving understanding of disease mechanisms, and facilitating the development of targeted therapeutic approaches with safer and more effective outcomes.[1] Advances in sequencing technologies and bioinformatics have enabled large-scale generation, storage, and analysis of genetic data, facilitating improved understanding of disease mechanisms, more accurate disease risk prediction, and the development of targeted therapeutic approaches.[2] These developments have also facilitated reuse of genetic information beyond the original purpose for which such information was obtained.[3]

However, the rapid expansion in the generation, storage, and reuse of genetic data has introduced a complex set of ethical, legal, and social challenges related to ownership, privacy, consent, and governance of genetic information.[4] Unlike conventional medical data, genetic information is permanent, predictive, familial, and inherently identifiable. As clinical trials increasingly incorporate genomic components, questions surrounding secondary use of genetic data have become increasingly important. Many scholars therefore argue that genetic information requires greater protection than other forms of health data, a concept commonly referred to as “genetic exceptionalism.”[5]

In this context, the study by Devarinti et al.[6] published in the Perspectives in Clinical Research provides timely and important insights into stakeholder perspectives on ethical issues related to genetic data reuse within clinical trials. Major concerns identified among various stakeholders were misuse of genetic data, confidentiality, intentional disclosure of information, and ethical and legal issues related to genetic data reuse. Secondary use of stored samples, return of research results, optional genomic research in clinical trials, and proper coding of genetic data were also important concerns among stakeholders. Interestingly, unrestricted data sharing generated comparatively less concern among stakeholders, reflecting the complex balance between facilitating scientific advancement and ensuring responsible governance of genetic information.

The findings are particularly relevant in the current era of expanding genomic databases, biobanking, and multinational collaborative research, where reuse of stored genetic data has become increasingly common. Importantly, the study emphasizes the need for transparent, participant-centered, and ethically robust governance frameworks for genomic research.

The concerns regarding secondary use of stored samples and genetic data highlighted in the article further underscore the limitations of traditional one-time consent approaches in genomic research. Although broad consent models are operationally convenient, they may not fully address stakeholder concerns related to future data use, confidentiality, and participant control over genetic information.[7] Different consent models, including blanket, broad, specific, dynamic, and meta consent, have therefore been proposed for management and reuse of genetic information.[8] While blanket and broad consent facilitate future research use of stored samples, specific consent requires participant approval for each individual study. Dynamic and meta consent models attempt to provide greater participant engagement and flexibility by allowing individuals to customize or modify consent preferences over time. However, regardless of the consent model adopted, ethical acceptability of genetic data reuse depends largely on transparency, confidentiality safeguards, participant rights, and effective ethics committee oversight.[8]

As highlighted by Petrini,[7] biological samples and data are often collected without explicit consent for future reuse, giving rise to ethical tensions involving confidentiality, autonomy, research priorities, advancement of knowledge, and public trust in scientific institutions. Such approaches recognize that consent in genomic research should not be viewed as a single event but rather as a continuous process responsive to changing scientific context. McGuire and Beskow emphasized that informed consent in genomic research requires approaches that acknowledge the long-term and evolving nature of genetic data use.[9]

Closely intertwined with issues of consent are concerns regarding privacy and data security. Genetic data remains inherently identifiable because of its unique and immutable nature, and advances in genomic databases and data analytics have increased the risk of re-identification. Stakeholders surveyed in the study by Devarinti et al. expressed concerns regarding unauthorized access, misuse of information, confidentiality breaches, and discriminatory practices.[6] Ethical analyses have similarly highlighted risks such as insurance discrimination, employment bias, stigmatization, and psychosocial harm associated with misuse of genetic information.[8,10] These concerns are further amplified by increasing storage of genetic data in institutional repositories and digital databases where governance and access control mechanisms may vary. In India, the Digital Personal Data Protection Act, 2023,[11] represents an important step toward strengthening protection of personal data, including sensitive health-related information. However, application of these provisions to genomic data reuse and cross-border sharing in research settings may require further clarification. In many biobank systems, reuse of stored data is linked to scientific and ethics oversight processes, whereas institutional repositories may not always operate under similarly standardized safeguards.[10]

In this context, robust data governance mechanisms are essential. Transparency in how genetic data are stored, shared, and reused is critical for maintaining public trust and ensuring responsible data sharing practices.[12] Without such trust, willingness of individuals to participate in genomic research may be adversely affected, ultimately limiting scientific advancement.[13]

An important contribution of the study by Devarinti et al.[6] lies in highlighting the diversity of ethical concerns among different stakeholder groups involved in genetic data reuse. Misuse of genetic data, confidentiality, intentional disclosure of information, and ethical and legal issues emerged as major concerns across stakeholders. Interestingly, unrestricted data sharing in research generated comparatively less concern among stakeholders, reflecting the complex balance between facilitating scientific advancement and ensuring responsible governance of genetic information.

Previous research examining participant perspectives has similarly identified trust, transparency, and perceived benefit sharing as key determinants of acceptance of data reuse.[14]

The global regulatory landscape is also evolving in response to these challenges. The World Health Organization has recently articulated a set of guiding principles for the ethical collection, access, use, and sharing of human genomic data.[15] These principles emphasize respect for persons, equity, transparency, accountability, and responsible data stewardship. Importantly, they advocate for fair benefit sharing, particularly in contexts where genomic research involves populations from low- and middle-income countries. This is especially relevant in the Indian context, where increasing participation in global clinical trials necessitates alignment with international ethical standards while addressing local sociocultural and regulatory realities.

Despite these advances, significant gaps remain in existing regulatory frameworks. Many national guidelines provide broad direction on data protection and informed consent but lack specific provisions addressing complexities related to genetic data reuse, long-term storage, cross-border data transfer, and governance of biobanks. In India, guidance from the Indian Council of Medical Research,[16] including the National Guidelines for Gene Therapy Product Development and Clinical Trials[17] released in collaboration with the Department of Biotechnology, provides an important ethical and regulatory foundation for clinical research. However, more explicit frameworks tailored to genomic research and secondary data use are still needed. Recent emphasis on research audits and accountability further highlights the importance of strengthening governance mechanisms.

Within this evolving landscape, the role of ethics committees assumes heightened significance. Beyond protocol review, ethics committees must increasingly oversee issues related to data governance, future reuse of samples, confidentiality safeguards, and ethical management of research findings. Capacity building in genomic science, data protection, and digital ethics will therefore be essential to enable effective oversight in modern genomic research settings.

In conclusion, reuse of genetic data in clinical research offers immense potential for advancing medical knowledge and improving patient care, but it also demands continuous re-evaluation of existing ethical frameworks. Strengthening consent processes, ensuring robust data governance, and promoting transparent stakeholder engagement will be essential for responsible genomic research. As genomic science continues to evolve, the success of future research will depend not only on scientific innovation but also on the ethical integrity, public trust, and governance systems that support it.